Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

10:16
12/01/16
12/01
10:16
12/01/16
10:16

bluebird bio BCMA CAR-T results early, but encouraging, says Piper Jaffray

Piper Jaffray analyst Joshua Schimmer noted that bluebird bio's interim data from its ongoing Phase 1 study of bb2121, the company's investigational anti-BCMA CAR-T candidate in patients with relapsed/refractory multiple myeloma, showed that four of nine patients achieved partial responses and two patients achieved stringent complete responses. While results are early, they are also encouraging, said Schimmer, who has an Overweight rating on bluebird shares.

  • 01

    Dec

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
12/01/16
WELS
12/01/16
NO CHANGE
WELS
bluebird bio data positive, says Wells Fargo
After bluebird bio announced interim Phase 1 dose escalation data for its CAR T product bb2121 in patients with relapsed/refractory multiple myeloma, Wells Fargo says the data shows that the product provides "a profound benefit for patients exhausting available treatment options." Wells thinks that the product could be approved on an accelerated timetable, and it keeps an Outperform rating on the stock.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.

TODAY'S FREE FLY STORIES

ROST

Ross Stores

$57.78

1.25 (2.21%)

06:42
06/29/17
06/29
06:42
06/29/17
06:42
Technical Analysis
Technical View: Ross Stores gives back prior day gains in pre-market »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCMLY

LafargeHolcim

$11.78

0.115 (0.99%)

06:42
06/29/17
06/29
06:42
06/29/17
06:42
Downgrade
LafargeHolcim rating change  »

LafargeHolcim downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$17.15

0.5 (3.00%)

06:40
06/29/17
06/29
06:40
06/29/17
06:40
Technical Analysis
Technical View: Valeant moves higher in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

, BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

06:38
06/29/17
06/29
06:38
06/29/17
06:38
Hot Stocks
Home Capital gets TSX approval for equity investment by Berkshire Hathaway »

Home Capital Group is…

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRO

Monro Muffler

$41.70

-3.45 (-7.64%)

06:36
06/29/17
06/29
06:36
06/29/17
06:36
Downgrade
Monro Muffler rating change  »

Monro Muffler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFS

CHF Solutions

$0.62

-0.0074 (-1.17%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Initiation
CHF Solutions initiated  »

CHF Solutions initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$98.95

0.42 (0.43%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Earnings
McCormick backs FY17 adj. EPS view of $4.05-$4.13 »

Sees FY17 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

MKC

McCormick

$98.95

0.42 (0.43%)

06:31
06/29/17
06/29
06:31
06/29/17
06:31
Earnings
McCormick reports Q2 adj. EPS 82c, consensus 76c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

06:25
06/29/17
06/29
06:25
06/29/17
06:25
Recommendations
Pier 1 Imports analyst commentary  »

Pier 1 Imports shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

06:22
06/29/17
06/29
06:22
06/29/17
06:22
Recommendations
Weibo analyst commentary  »

Weibo content block to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

, SINA

SINA

$86.75

1.78 (2.09%)

06:18
06/29/17
06/29
06:18
06/29/17
06:18
Periodicals
China's Weibo to block unlicensed video conternt, Reuters reports »

China's Weibo (WB)…

WB

Weibo

$69.36

0.28 (0.41%)

SINA

SINA

$86.75

1.78 (2.09%)

FENG

Phoenix New Media

$2.70

-0.04 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$27.83

-0.35 (-1.24%)

06:13
06/29/17
06/29
06:13
06/29/17
06:13
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$37.89

0.65 (1.75%)

06:10
06/29/17
06/29
06:10
06/29/17
06:10
Recommendations
Allison Transmission analyst commentary  »

Piper 'growing more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$27.69

1.13 (4.25%)

06:05
06/29/17
06/29
06:05
06/29/17
06:05
Hot Stocks
Noah Holdings authorizes $50M share repurchase program »

Noah Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Earnings
Greenbrier sees FY17 EPS $3.45-$3.65, consensus $3.49 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

PDS

Precision Drilling

$3.36

0.03 (0.90%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Downgrade
Precision Drilling rating change  »

Precision Drilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:03
06/29/17
06/29
06:03
06/29/17
06:03
Earnings
Greenbrier reports Q3 EPS $1.03, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

SPX

S&P 500

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.00

0.46 (7.03%)

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Recommendations
ImmunoGen analyst commentary  »

ImmunoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.43

0.17 (0.76%)

05:58
06/29/17
06/29
05:58
06/29/17
05:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.90

0.09 (0.08%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.99

0.49 (1.56%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$19.69

0.8 (4.24%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$29.70

-0.63 (-2.08%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.67

-2.77 (-4.37%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.